WO2005016323A2 - Use of c-kit inhibitors for treating type ii diabetes - Google Patents
Use of c-kit inhibitors for treating type ii diabetes Download PDFInfo
- Publication number
- WO2005016323A2 WO2005016323A2 PCT/IB2004/002934 IB2004002934W WO2005016323A2 WO 2005016323 A2 WO2005016323 A2 WO 2005016323A2 IB 2004002934 W IB2004002934 W IB 2004002934W WO 2005016323 A2 WO2005016323 A2 WO 2005016323A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- phenyl
- thiazol
- ylamino
- pyridin
- Prior art date
Links
- 0 CC1=*CC(c2ccccc2)=CS1 Chemical compound CC1=*CC(c2ccccc2)=CS1 0.000 description 8
- PIMXRRUSFWCJKP-UHFFFAOYSA-N CC1NC=CC=C1c1c[s]c(Nc2c(C)ccc(NCc(cc3)ccc3C(OC)=O)c2)n1 Chemical compound CC1NC=CC=C1c1c[s]c(Nc2c(C)ccc(NCc(cc3)ccc3C(OC)=O)c2)n1 PIMXRRUSFWCJKP-UHFFFAOYSA-N 0.000 description 1
- RUBGHVAGMCAJAT-UHFFFAOYSA-N Cc(ccc(NC(c(cc1)ccc1NC(Nc1ccc[s]1)=O)O)c1)c1Nc1nc(-c2cccnc2)c[s]1 Chemical compound Cc(ccc(NC(c(cc1)ccc1NC(Nc1ccc[s]1)=O)O)c1)c1Nc1nc(-c2cccnc2)c[s]1 RUBGHVAGMCAJAT-UHFFFAOYSA-N 0.000 description 1
- SBWXEKIDMSQTJT-UHFFFAOYSA-N Cc(ccc(NC(c1cc(Cl)c(CN2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2cccnc2)c[s]1 Chemical compound Cc(ccc(NC(c1cc(Cl)c(CN2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2cccnc2)c[s]1 SBWXEKIDMSQTJT-UHFFFAOYSA-N 0.000 description 1
- VPUCPFOMKBFXJE-UHFFFAOYSA-N Cc(ccc(NC(c1cc(N2CCN(C)CC2)ccc1)=O)c1)c1Nc1nc(-c2cnccc2)c[s]1 Chemical compound Cc(ccc(NC(c1cc(N2CCN(C)CC2)ccc1)=O)c1)c1Nc1nc(-c2cnccc2)c[s]1 VPUCPFOMKBFXJE-UHFFFAOYSA-N 0.000 description 1
- HQURGOWSSLSRJM-UHFFFAOYSA-N Cc(ccc(NC(c1cc([Br]=C)c(CNCCCN2CCOCC2)c(Br)c1)=O)c1)c1Nc1nc(-c2cccnc2)c[s]1 Chemical compound Cc(ccc(NC(c1cc([Br]=C)c(CNCCCN2CCOCC2)c(Br)c1)=O)c1)c1Nc1nc(-c2cccnc2)c[s]1 HQURGOWSSLSRJM-UHFFFAOYSA-N 0.000 description 1
- ZMACZMJSTAKFRT-UHFFFAOYSA-N Cc(ccc(NC(c1ccc(CN2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2ncc[s]2)c[s]1 Chemical compound Cc(ccc(NC(c1ccc(CN2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2ncc[s]2)c[s]1 ZMACZMJSTAKFRT-UHFFFAOYSA-N 0.000 description 1
- APUQHEUVLUFGOT-UHFFFAOYSA-N Cc(ccc(NC(c1cccc(I)c1)=O)c1)c1Nc1nc(-c2cccnc2)c[s]1 Chemical compound Cc(ccc(NC(c1cccc(I)c1)=O)c1)c1Nc1nc(-c2cccnc2)c[s]1 APUQHEUVLUFGOT-UHFFFAOYSA-N 0.000 description 1
- BXSXHHGNJLSHQZ-UHFFFAOYSA-N Cc1cc(-c2c[s]c(Nc3c(C)ccc(NC(c4ccc(CN5CCN(C)CC5)cc4)=O)c3)n2)c(C)cc1 Chemical compound Cc1cc(-c2c[s]c(Nc3c(C)ccc(NC(c4ccc(CN5CCN(C)CC5)cc4)=O)c3)n2)c(C)cc1 BXSXHHGNJLSHQZ-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a method for treating type II diabetes, obesity and related disorders comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation, to a human in need of such treatment.
- a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors.
- said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
- Non-insulin-dependent diabetes mellitus also known as type IT diabetes, is defined as a chronic disease appearing when the insulin turns out to be inefficient in promoting glucose uptake by cells, which results in increased levels of glucose in the blood. This disease affects about 100 million people world-wide, 75% of which are obese at the time of diagnosis.
- Hypoglycemic agents such as sulfonylureas work by triggering the pancreas to make more insulin, which lower blood glucose.
- the side effects of sulfonylureas include hypoglycemia, renal and hepatic disease, gastrointestinal disturbances, increased cardiovascular mortality, dermatological reactions, drowsiness and headache. Biguanides lower blood glucose levels by reducing intestinal glucose absorption and hepatic glucose, but not by stimulating insulin secretion.
- the major side effects of biguanidine are lactic acidosis and increased cardiovascular mortality.
- Alpha-glucosidase inhibitors decrease the absorption of carbohydrates from the digestive tract, thereby lowering the after-meal glucose level, but gastrointestinal side effects and hypoglycemia are observed.
- Thiazolidinediones such as rosiglitazone are PPARgamma agonists and increase the cell's sensitivity to insulin. However, they may be responsible for water retention, liver diseases, cardiovascular diseases, red blood cell abnormalities, and headache.
- c-kit inhibitors lower the level of glucose, cholesterol, triglycerides and non esterified fatty acids in blood.
- adipose tissue is a dynamic endocrine organ that secretes a number of factors that are increasingly recognized to contribute to systemic and vascular inflammation.
- adipokines The major secretory compartment of adipose tissue consists of adipocytes, fibroblasts, and mast cells. These cells, using endocrine, paracrine and autocrine pathways, secrete multiple bioactive molecules, conceptualized as "adipokines".
- mast cells regulate, directly or indirectly, a number of the processes that contribute to the development of atherosclerosis, including hypercholesterolemia, hypergycemia, hypertension, endothelial dysfunction, insulin resistance, and vascular remodeling. But, as this point, other mechanisms may not be ruled out.
- a new route for treating type H diabetes, obesity and related disorders is provided, which consists of administering c-kit inhibitors to patients.
- the present invention relates to a method for treating type IT diabetes, obesity and related disorders comprising administering a compound capable of depleting mast cells or blocking mast cells degranulation to a human in need of such treatment.
- Said method for treating type II diabetes can comprise administering a c-kit inhibitor to a human in need of such treatment
- it may also consist of administering an antihistamine compound or a compound that blocks mast cells exocytosis such as the Rigel's pharmaceuticals Rl 12.
- Preferred compounds are c-kit inhibitor, more particularly a non-toxic, selective and potent c-kit inhibitor.
- Such inhibitors can be selected from the group consisting of 2-(3- amino)arylamino-4-aryl-thiazoles, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl- quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.
- pyrimidine derivatives such as N-phenyl-2-pyrimidine-amine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504), US 5,883,116, US 5,883,113, US 5, 886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940), 4-amino-substituted quinazolines (US 3,470,182), 4Jhienyl-2-(lH)-quinazolones, 6,7-dialkoxyquinazolines (US 3,800,
- the invention relates to a method for treating type TJ diabetes comprising administering a non toxic, potent and selective c-kit inhibitor is a pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives of formula I :
- Rl, R2, R3, R13 to R17 groups have the meanings depicted in EP 564409 Bl, inco ⁇ orated herein in the description.
- the N-phenyl-2-pyrimidine-amine derivative is selected from the compounds corresponding to formula LT :
- Rl, R2 and R3 are independently chosen from H, F, CI, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;
- R4, R5 and R6 are independently chosen from H, F, CI, Br, I, a C1-C5 alkyl, especially a methyl group; and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function.
- R7 is the following group :
- Rl is a heterocyclic group, especially a pyridyl group
- R2 and R3 are H
- R4 is a C1-C3 alkyl, especially a methyl group
- R5 and R6 are H
- R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, for example the group :
- the invention relates to a method for treating type IT diabetes comprising the administration of an effective amount of the compound known in the art as CGP57148B : 4-(4-mehylpiperazine-l-ylmethyl)-N-[4-methyl-3-(4-pyridine-3-yl)pyrimidine-2 ylamino)phenyl]-benzamide corresponding to the following formula :
- the c-kit inhibitor can be selected from :
- indolinone derivatives more particularly pyrrol-substituted indolinones
- quinaxolines such as 2-phenyl-quinaxoline derivatives, for example 2-phenyl- 6,7-dimethoxy quinaxoline.
- the invention contemplated the method mentioned above, wherein said c-kit inhibitor is selected from 2-(3-amino)arylamino-4- aryl-thiazoles such as those chosen from formula III for which the applicant filed US 60/400064 :
- R 1 is : a) a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; b) an aryl or heteroaryl group optionally substituted by an alkyl or aryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; c) a -CO-NH-R, -CO-R, -CO-OR or a -CO-NRR' group, wherein R and R' are independently chosen from H or an aryl, heteroaryl, alkyl and cycloalkyl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R 2 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 3 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 4 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 5 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 6 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- R 7 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-th ⁇ enyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- H a halogen selected from I, F, CI or Br
- NH2, NO2 or SO2-R wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI,
- R is H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F and / or bearing a pendant basic nitrogen functionality.
- R is H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F and / or bearing a pendant basic nitrogen functionality; or a a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F and / or bearing a pendant basic nitrogen functionality; a -SO2-R group wherein R is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F and /
- R is H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or an alkyl, cycloalkyl, aryl or heteroaryl group substituted by a alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; a -SO2-R group wherein R is an alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with an heteroatom, notably a
- R is H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F and / or bearing a pendant basic nitrogen functionality; or an alkyl, cycloalkyl, aryl or heteroaryl group substituted by a alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F and / or bearing a pendant basic nitrogen functionality; a -SO2-R group wherein R is an alkyl, cycloalkyl, aryl or heteroaryl group optionally substituted with at
- R is H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality.
- Y is a linear or branched alkyl group containing from 1 to 10 carbon atoms; wherein Z represents an aryl or heteroaryl group, optionally substituted at one or more ring position with any permutation of the following groups: - a halogen such as F, CI, Br, I; - a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a hal
- Ra and Rb represents a hydrogen, or a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality or a cycle; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- Ra and Rb are a hydrogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- Ra and Rb are a hydrogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; - an OSO R, where R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally
- R »2 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy
- R 3 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy
- R 4 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy
- R 5 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy
- R 6 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- H a halogen selected from I, F, CI or Br
- NH2, NO2 or SO2-R wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI,
- R 7 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- H an halogen selected from I, F, CI or Br; NH2, NO2 or SO2-R, wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality.
- the invention is particularly embodied by the compounds of the following formula TV :
- X is R or NRR' and wherein R and R' are independently chosen from H, an aryl, a heteroaryl, an alkyl , or a cycloalkyl group optionally substituted with at least one heteroatom, such as for example a halogen chosen from F, I, CI and Br and optionally bearing a pendant basic nitrogen functionality; or an aryl, a heteroaryl, an alkyl or a cycloalkyl group substituted with an aryl, a heteroaryl, an alkyl or a cycloalkyl group optionally substituted with at least one heteroatom, such as for example a halogen chosen from F, I, CI and Br and optionally bearing a pendant basic nitrogen functionality,
- R 2 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy
- R 3 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy
- R 4 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 5 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 6 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy.
- R6 which in the formula IT is connected to position 4 of the thiazole ring, may instead occupy position 5 of the thiazole ring.
- the invention is directed to compounds in which X is a substituted alkyl, aryl or heteroaryl group bearing a pendant basic nitrogen functionality represented for example by the structures a to f shown below, wherein the wavy line corresponds to the point of attachment to core structure of formula IV:
- X (see formula TJ) is preferentially group d.
- the invention concerns the compounds in which R 2 and R 3 are hydrogen.
- R 4 is a methyl group and R 5 is H.
- R 6 is preferentially a 3-pyridyl group (cf. structure g below), or a 4-pyridyl group (cf. structure h below).
- the wavy line in structure g and h correspond to the point of attachment to the core structure of formula HI or IV.
- the invention contemplates: 1- A compound of formula TV as depicted above, wherein X is group d and R 6 is a 3-pyridyl group.
- 2- A compound of formula TV as depicted above, wherein X is group d and R 4 is a methyl group.
- 3- A compound of formula TIT or TV as depicted above, wherein R 1 is group d and R 2 is H.
- 4- A compound of formula TH or IV as depicted above, wherein R 1 is group d and R 3 is H.
- 5- A compound of formula TIT or IV as depicted above, wherein R 1 is group d and R 2 and/or R 3 and or R 5 is H.
- 6- A compound of formula TIT or IV as depicted above, wherein R 6 is a 3-pyridyl group and R 3 is a methyl group.
- 7- A compound of formula Til or IV as depicted above, wherein R 6 is a 3-pyridyl group and R 2 is H.
- 8- A compound of formula TIT or TV as depicted above, wherein R and/or R and/or R 5 is H and R 4 is a methyl group.
- 9- A compound of formula III or TV as depicted above wherein R 2 and/or R 3 and/or R 5 is H, R 4 is a methyl group and R 6 is a 3-pyridyl group.
- the invention is particularly embodied by the compounds wherein R2, R3, R5 are hydrogen, corresponding to the following formula rv-i :
- X is R or NRR' and wherein R and R' are independently chosen from H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; a -SO2-R group wherein R is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with a heteroatom, notably a halogen selected from I
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- H a halogen selected from I, F, CI or Br
- NH2, NO2 or SO2-R wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI,
- substituent R6 which in the formula TT is connected to position 4 of the thiazole ring, may instead occupy position 5 of the thiazole ring.
- Ra, Rb are independently chosen from H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; a -SO2-R group wherein R is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing
- R 4 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy
- R 6 is one of the following: (i) an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy; (ii) a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy.
- H a halogen selected from I, F, CI or Br
- NH2, NO2 or SO2-R wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality.
- 012 1 -(4-Fluoro-phenyl)-3-[4-methyl-3-(4-pyridin -3-yl-thiazol-2 -ylamino)-phenyl] -urea
- 017 l-(2,4-Dimethoxy-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)- phenyl]-urea
- 018 l-(2Jodo-phenyl)-l-(N(2Jodo-phenyl)-formamide)-3-[4-methyl-3-(4-pyridin-3-yl- thiazol-2-ylamino)-phenyl]-urea
- 019 l-(3,5-Dimethyl-isoxazol-4-yl)-3-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)- phenyl]-urea
- the invention is particularly embodied by the compounds wherein X is a -substituted Aryl group, corresponding to the N-[3-(Thiazol- 2-ylamino)-phenyl]-amide family and the following formula IV-3 :
- Ra, Rb, Re, Rd, Re are independently chosen from H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; a -SO2-R group wherein R is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with a heteroatom, notably a halogen selected from I,
- R 6 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- H a halogen selected from I, F, CI or Br
- NH2, NO2 or SO2-R wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI,
- the invention is particularly embodied by the compounds wherein X is a -substituted-aryl group, corresponding to the 4-(4- substituted-l-ylmethyl)-N[3-(thiazol-2-ylamino)-phenyl]-benzamide family and the following formula IV-4 :
- X is a heteroatom, such as O or N
- Ra, Rb, Rd, Re, Rf, Rg, Rh are independently chosen from H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- R and R' are H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; a -SO2-R' group wherein R' is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- Ra and Rb are H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- Ra and Rb are H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- Ra and Rb are a hydrogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; - an OSO 2 R, where R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen)
- Ra and Rb are a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality;
- Ra can also be a hydrogen; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a -CO-R or a -CO-NRR' group, wherein R and R' are independently chosen from H, an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality.
- Ra, Rb, Rd, Re can also be halogen such as CI, F, Br, I or trifluoromethyl;
- R 4 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 6 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy; iv) H, a halogen selected from I, F, CI or Br; NH2, NO2 or SO2-R, wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality.
- substituents such as halogen, an alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy
- H a halogen selected from I, F, CI
- the invention is particularly embodied by the compounds wherein X is a -aryl-substituted group, corresponding to the 3-Disubstituted- amino-N[3-(thiazol-2-ylamino)-phenyl]-benzamide family and the following formula
- Ra, Rb, Re, Re, Rf, Rg are independently chosen from H or an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- R and R' are H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- R is H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; a -SO2-R' group wherein R' is an alkyl, cycloalkyl, aryl or heteroaryl optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- Ra and Rb are H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- Ra and Rb are H or a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- Ra and Rb are a hydrogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- R is a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality;
- Ra and Rb are a linear or branched alkyl group containing from 1 to 10 carbon atoms atoms optionally substituted with at least one heteroatom (for example a halogen) and / or bearing a pendant basic nitrogen functionality; Ra can also be a hydrogen; a cycloalkyl, an aryl or heteroaryl group optionally substituted with at least one heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group substituted by an alkyl, a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F, and / or bearing a pendant basic nitrogen functionality; - or a -SO2-R group wherein R is an alkyl, cycloalkyl, aryl
- Ra, Rb, Re, Re can also be halogen such as CI, F, Br, I or trifluoromethyl;
- R 4 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 6 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- H a halogen selected from I, F, CI or Br
- NH2, NO2 or SO2-R wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI,
- the invention is particularly embodied by the compounds wherein X is a -OR group, corresponding to the family [3-(Thiazol-2- ylamino)-phenyl]-carbamate and the following formula IV-6
- R is independently chosen from an organic group that can be selected for example from a linear or branched alkyl group containing from 1 to 10 carbon atoms optionally substituted with at least one heteroatom and / or bearing a pendant basic nitrogen functionality; a cycloalkyl, an aryl or heteroaryl group optionally substituted with an heteroatom, notably a halogen selected from I, CI, Br and F and / or bearing a pendant basic nitrogen functionality; or a cycloalkyl, an aryl or heteroaryl group optionally substituted with a cycloalkyl, an aryl or heteroaryl group optionally substituted with a heteroatom, notably a halogen selected from I, CI, Br and F and / or bearing a pendant basic nitrogen functionality; R 4 is hydrogen, halogen or a linear or branched alkyl group containing from 1 to 10 carbon atoms, trifluoromethyl or alkoxy;
- R 6 is one of the following:
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl, and alkoxy;
- a heteroaryl group such as a 2, 3, or 4-pyridyl group, which may additionally bear any combination of one or more substituents such as halogen, alkyl groups containing from 1 to 10 carbon atoms, trifluoromethyl and alkoxy;
- a five-membered ring aromatic heterocyclic group such as for example 2-thienyl, 3- thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, which may additionally bear any combination of one or more substituents such as halogen, an alkyl group containing from
- H a halogen selected from I, F, CI or Br
- NH2, NO2 or SO2-R wherein R is a linear or branched alkyl goup containing one or more group such as 1 to 10 carbon atoms, and optionally substituted with at least one heteroatom, notably a halogen selected from I, CI,
- Substituent "L” in formula 10 is a nucleofugal leaving group in nucleophilic substitution reactions (for example, L can be selected from chloro, bromo, iodo, toluenesulfonyloxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, etc., with L being preferentially a bromo group).
- Group Rl in formula 11a corresponds to group Rl as described in formula m.
- Group "PG" in formula 1 lc is a suitable protecting group of a type commonly utilized by the person skilled in the art.
- Formula 12b describes a precursor to compounds of formula III which lack substituent Rl. Therefore, in a second phase of the synthesis, substituent Rl is connected to the free amine group in 12b, leading to the complete structure embodied by formula Til: 12b + "Rl" -> ⁇ T
- Rl the nature of which is as described on page 3 for the general formula HI, is achieved by the use of standard reactions that are well known to the person skilled in the art, such as alkylation, acylation, sulfonylation, formation of ureas, etc.
- Formula 12c describes an N-protected variant of compound 12b.
- Group "PG" in formula 12c represents a protecting group of the type commonly utilized by the person skilled in the art. Therefore, in a second phase of the synthesis, group PG is cleaved to transform compound 12c into compound 12b. Compound 12b is subsequently advanced to structures of formula I as detailed above.
- Formula 12d describes a nitro analogue of compound 12b.
- the nitro group of compound 12d is reduced by any of the several methods utilized by the person skilled in the art to produce the corresponding amino group, namely compound 12b.
- Compound 12b thus obtained is subsequently advanced to structures of formula m as detailed above.
- aqueous phase was then basified (pH>12) by addition of 2.5N aqueous sodium hydroxyde solution.
- the crude product was extracted with ethyl acetate (4x30 mL). The combined organic layers were dried over MgSO 4 and concentrated under reduced pressure to afford a slightly yellow oil which became colorless after purification by Kugelrohr distillation (190°C) in 68% yield.
- Benzoyl chloride (5.64 g, 80 mmol) was added dropwise to a well-stirred solution of ammonium thiocyanate (3.54 g, 88 mmol) in acetone (50 mL). The mixture was refluxed for 15 min, then, the hydrobromide salt of 2-methyl-5-tert-butoxycarbonylamino-aniline (8.4g, 80 mmol) was added slowly portionswise. After lh, the reaction mixture was poured into ice-water (350 mL) and the bright yellow precipitate was isolated by filtration. This crude solid was then refluxed for 45 min in 70 mL of 2.5 N sodium hydroxide solution. The mixture was cooled down and basified with ammonium hydroxide.
- type TT diabetes as referred herein includes obesity, hypercholesterolemia, hypergycemia, hypertension, endothelial dysfunction, insulin resistance, and vascular remodelling.
- c-kit inhibitors as mentioned above are inhibitors of activated c-kit.
- the expression "activated c-kit” means a constitutively activated-mutant c-kit including at least one mutation selected from point mutations, deletions, insertions, but also modifications and alterations of the natural c-kit sequence (SEQ TD N°l). Such mutations, deletions, insertions, modifications and alterations can occur in the transphosphorylase domain, in the juxtamembrane domain as well as in any domain directly or indirectly responsible for c-kit activity.
- the expression “activated c- kit” also means herein SCF-activated c-kit.
- Preferred and optimal SCF concentrations ⁇ c for activating c-kit are comprised between 5.10 " M and 5.10 " M, preferably around 2.10 " M.
- the activated-mutant c-kit in step a) has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ TD No 1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants.
- the activated-mutant c-kit in step a) has a deletion in the juxtamembrane domain of c-kit. Such a deletion is for example between codon 573 and 579 called c-kit d(573-579).
- the point mutation V559G proximal to the juxtamembrane domain c-kit is also of interest.
- the invention contemplates a method for treating type TT diabetes as defined above comprising administering to a human in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises : a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex, b) selecting compounds that inhibit activated c-kit, c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of TL-3.
- This screening method can further comprise the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit (for example in the transphosphorylase domain), which are also capable of inhibiting SCF- activated c-kit wild.
- activated c-kit is SCF-activated c-kit wild.
- a best mode for practicing this method consists of testing putative inhibitors at a concentration above 10 ⁇ M in step a). Relevant concentrations are for example 10, 15, 20, 25, 30, 35 or 40 ⁇ M.
- TL-3 is preferably present in the culture media of TL-3 dependent cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.
- TL-3 dependent cells include but are not limited to :
- human mast cell lines naturally expressing and depending on c-kit for growth and survival.
- human mast cell lines can be established using the following procedures : normal human mast cells can be infected by retroviral vectors containing sequences coding for a mutant c-kit comprising the c-kit signal peptide and a TAG sequence allowing to differentiate mutant c-kits from c-kit wild expressed in hematopoetic cells by means of antibodies.
- CD34+ cells are then cultured at 37°C in 5 % CO 2 atmosphere at a concentration of 10 5 cells per ml in the medium MCCM ( ⁇ -MEM supplemented with L-glutamine, penicillin, streptomycin,- 5 10 "5 M ⁇ -mercaptoethanol, 20 % veal foetal serum, 1 % bovine albumin serum and 100 ng/ml recombinant human SCF.
- the medium is changed every 5 to 7 days.
- the percentage of mast cells present in the culture is assessed each week, using May-Grunwal Giemsa or Toluidine blue coloration.
- Anti-tryptase antibodies can also be used to detect mast cells in culture.
- c-kit After 10 weeks of culture, a pure cellular population of mast cells (> 98 %) is obtained. It is possible using standard procedures to prepare vectors expressing c-kit for transfecting the cell lines established as mentioned above.
- the cDNA of human c-kit has been described in Yarden et al., (1987) EMBO J.6 (11), 3341-3351.
- the coding part of c-kit (3000 bp) can be amplified by PCR and cloned, using the following oligonucleotides : 5 ⁇ AGAAGAGATGGTACCTCGAGGGGTGACCC3' (SEQ TD No2) sens 5'CTGCTTCGCGGCCGCGTTAACTCTTCTCAACCA3' (SEQ TD No3) antisens
- the PCR products, digested with Notl and Xhol, has been inserted using T4 ligase in the pFlag-CMV vector (SIGMA), which vector is digested with Notl and Xhol and dephosphorylated using OP (Biolabs).
- the pFlag-CMV-c-kit is used to transform bacterial clone XLl-blue.
- the transformation of clones is verified using the following primers : - 5 ⁇ GCTCGTTTAGTGAACCGTC3' (SEQ TD No4) sens, - 5'GTCAGACAAAATGATGCAAC3' (SEQ TD No5) antisens.
- the vector Migr-1 (ABC) can be used as a basis for constructing retroviral vectors used for transfecting mature mast cells.
- This vector is advantageous because it contains the sequence coding for GFP at the 3' and of an IRES.
- TL-3 dependent cell lines that can be used include but are not limited to: - BaF3 mouse cells expressing wild-type or mutated form of c-kit (in the juxtamembrane and in the catalytic sites) are described in Kitayama et al, (1996), Blood 88, 995-1004 and Tsujimura et al, (1999), Blood 93, 1319-1329. - IC-2 mouse cells expressing either c-kit or c-k_P l are presented in Piao et al, (1996), Proc. Natl. Acad. Sci. USA 93, 14665-14669.
- TL-3 independent cell lines are :
- - HMC-1 a factor-independent cell line derived from a patient with mast cell leukemia, expresses a juxtamembrane mutant c-kit polypeptide that has constitutive kinase activity (Furitsu T et al, J Clin Invest. 1993;92:1736-1744 ; Butterfield et al, Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345- 355 and Nagata et al, Proc Natl Acad Sci U S A. 1995;92:10560-10564).
- - P815 cell line mastocytoma naturally expressing c-kit mutation at the 814 position has been described in Tsujimura et al, (1994), Blood 83, 2619-2626.
- component (ii) inhibits activated c-kit can be measured in vitro or in vivo.
- cell lines expressing an activated-mutant c-kit which has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ TD No 1 involved in c-kit autophosphorylation, notably the D816V,
- D816Y, D816F and D820G mutants are preferred.
- Example of cell lines expressing an activated-mutant c-kit are as mentioned above.
- the method further comprises the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration below
- compounds are identified and selected according to the method described above are potent, selective and non-toxic c-kit wild inhibitors.
- the screening method as defined above can be practiced in vitro.
- the inhibition of mutant-activated c-kit and/or c-kit wild can be measured using standard biochemical techniques such as immunoprecipitation and western blot.
- the amount of c-kit phosphorylation is measured.
- the invention contemplates a method for treating type TT diabetes as depicted above wherein the screening comprises : a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an IC50 ⁇ 10 ⁇ M, by measuring the extent of cell death, b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being TL-3 dependent cells cultured in presence of TL-3, to identify a subset of candidate compounds targeting specifically c- kit, c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an IC50 ⁇ 10 ⁇ M, preferably an IC50 ⁇ 1
- the extent of cell death can be measured by 3H thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide. These are common techniques routinely practiced in the art.
- the method according to the invention includes preventing, delaying the onset and/or treating type II diabetes and associated damages in humans.
- any compound capable of depleting mast cells can be used.
- Such compounds can belong to, as explicated above, tyrosine kinase inhibitors, such as c-kit inhibitors, but are not limited to any particular family so long as said compound shows capabilities to deplete mast cells.
- Depletion of mast cells can be evaluated using for example one of the mast cell lines depicted above using routine procedure. Best compounds are compounds exhibiting the greatest selectivity.
- Control cell lines include other hematopoeitic cells that are not mast cells or related cells or cell lines. These control cell lines include SCF independent expanded human CD34+ normal cells.
- control cells also include but are not limited to the human T lymphocyte Jurkat cell line (ATCC N° TIB- 152 and mutant cell lines derived thereof), the human B lymphocyte Daudi or Raji cell line (ATCC N° CCL-213 and CCL-86 respectively), the human monocytic U 937 cell line (ATCC N° CRL-1593.2) and the human HL-60 cell line (ATCC N° CCL-240) and mutant cell lines derived thereof CRL- 2258 and CRL-2392).
- human T lymphocyte Jurkat cell line ATCC N° TIB- 152 and mutant cell lines derived thereof
- the human B lymphocyte Daudi or Raji cell line ATCC N° CCL-213 and CCL-86 respectively
- the human monocytic U 937 cell line ATCC N° CRL-1593.2
- the human HL-60 cell line ATCC N° CCL-240
- Such compounds can be selected with a method for identifying compounds capable of depleting mast cells, said compound being non-toxic for cell types other than mast cells, comprising the step consisting of : a) culturing mast cells in vitro in a culture medium suitable for mast cells, b) adding to said culture medium at least one compound to be tested and incubating said cells for a prolonged period of time, c) selecting compounds that promote mast cells death, d) identifying a subset of compounds selected in step c) that are unable to promote death of cells selected from the above mentioned control cell lines.
- the invention embraces the use of the compounds defined above to manufacture a medicament for treating type II diabetes including obesity, hypercholesterolemia, hypergycemia, hypertension, endothelial dysfunction, insulin resistance, and vascular remodelling. More particularly, the above compounds are useful for preventing the onset or development of type IT diabetes in obese persons.
- compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, sublingual, or rectal means.
- these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).
- compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration.
- Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
- the invention relates to a pharmaceutical composition intended for oral administration.
- compositions suitable for use in the invention include compositions wherein compounds for depleting mast cells, such as c-kit inhibitors, or compounds inhibiting mast cells degranulation are contained in an effective amount to achieve the intended purpose.
- a therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition.
- Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population).
- the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
- Pharmaceutical compositions which exhibit large therapeutic indices are preferred.
- Example 1 Effect of different c-kit inhibitors on serum glucose, insulin, triglycerides, cholesterol and non esterified fatty acids levels in db/db mice
- the objective of this study is to assess the effects of different c-kit inhibitors on serum glucose, insulin, triglycerides, cholesterol and non esterified fatty acids levels in male db/db mice dosed orally, once-a-day, for 5 days.
- Substance tested code substances N°l and N°2 Reference substance Code : rosiglitazone 10 mg/kg Source : Sequoia Research Products Ltd, UK
- the vehicle will be defined by the Sponsor but, if no indication is supplied, a 3% Arabic gum aqueous solution (w/v) will be used.
- Group 1 vehicle Group 2 : test substance N°l, dose 1, route of administration
- Group 5 test substance N°2, dose 2, route of administration
- Group 6 rosiglitazone, 10 mg/kg, route of administration
- the doses will be expressed in terms of free active substance.
- test and reference substances will be extemporaneously prepared as instructed.
- test and reference substances and the vehicle will be administered in a volume of 5 ml/kg adjusted according to individual body weight values.
- mice will be weighed and blood samples will be collected through the retro-orbital plexus under isoflurane anesthesia. Blood samples will be kept at room temperature for 5 to 10 min to form a spontaneous clot, then put in ice until they are centrifuged at 3500 x g for 10-15 min at 4 °C. An aliquot of serum will be used for measuring glucose levels.
- Six groups of 5 mice will be formed with respect to homogeneous glycemia values by using a randomization table. Animal showing glycemia below 20 mM will be excluded from the study.
- mice From Tl to T5, the mice will be weighed and dosed once daily for 5 consecutive days at constant time.
- mice will be euthanized by cervical dislocation.
- Serum glucose and triglycerides levels will be determined using the Synchron CX4 analyzer. Serum non esterified fatty acids levels will be measured manually using a colorimetric method, and insulin levels determined by ELISA.
- a % of effect will be calculated according to following formula ((vehicle group - test group)/ vehicle group)* 100 Statistical analysis will consist in a one-way analysis of variance followed by multiple comparisons versus the vehicle group (Dunnett's test). In case the equal variance test fails, a Kruskall-Wallis one-way analysis of variance on ranks will be proposed. A difference will be considered significant for p ⁇ 0.05.
- Example 2 in vitro TK inhibition assays • Procedure Experiments were performed using purified intracellular domain of c-kit expressed in baculovirus. Estimation of the kinase activity was assessed by the phosphorylation of tyrosine containing target peptide estimated by established ELISA assay.
- Table 2 shows the potent inhibitory action of the catalytic activity of c-kit with an IC50 ⁇ 10 ⁇ M. Further experiments (not shown) indicates that at least one compound acts as perfect competitive inhibitors of ATP.
- Table 2 Compounds In vitro Inhibition assay results c-kit IC50 ( ⁇ M) 066; 074; 078; 084; 012; 016; 073; 021; 088; ⁇ 10 ⁇ M 023; 025; 047; 048; 055; 049; 026; 087; 075; 089; 051 082; 090 ; 060; 085; 052; 053, 096
- Ba/F3 murine kit and human kit are derived from the murine TL-3 dependent Ba/F3 proB lymphoid cells.
- the FMA3 and P815 cell lines are mastocytoma cells expressing endogenous mutated forms of Kit, i.e., frame deletion in the murine juxtamembrane coding region of the receptor-codons 573 to 579.
- the human leukaemic MC line HMC-1 expresses mutations JM-V560G; Immunoprecipitation assays and western blotting analysis
- 5.106 Ba/F3 cells and Ba/F3-derived cells with various c-kit mutations were lysed and immunoprecipitated as described (Beslu et ah, 1996), excepted that cells were stimulated with 250 ng / ml of rmKL.
- Cell lysates were immunoprecipitated with a rabbit immunserum anti murine KIT, directed against the KIT cytoplasmic domain (Rottapel et ah, 1991).
- Western blot was hybridized either with the 4G10 anti- phosphotyrosine antibody (UBI) or with the rabbit immunserum anti -murine KIT or with different antibodies (described in antibodies paragraph).
- the membrane was then incubated either with HRP-conjugated goat anti mouse IgG antibody or with HRP- conjugated goat anti rabbit IgG antibody (Immunotech), Proteins of interest were then visualized by incubation with ECL reagent (Amersham).
- Target IC50 Compounds c-Kit WT IC50 ⁇ 10 ⁇ M 002; 005; 006; 007; 008; 009; 010; 012; 017; 019; 020; 021; 023; 024; 025; 026; 028; 029; 030; 032; 042; 043; 045; 047; 048; 049; 050; 051 052053; 054; 055; 056 057; 059; 060; 061; 062; 063 064065; 066; 067; 072 073; 074; 075; 077; 078; 079 080081; 082; 083; 084 085; 086; 087; 088; 089; 090 092 093; 094; 095; 096 097; 106; 105; 104; 103;128 129 130; 131; 117;
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602004013792T DE602004013792D1 (en) | 2003-08-15 | 2004-08-16 | USE OF C-KIT INHIBITORS FOR THE TREATMENT OF TYPE-2 DIABETES |
US10/567,557 US20070032521A1 (en) | 2003-08-15 | 2004-08-16 | Use of c-kit inhibitors for treating type II diabetes |
CA002535242A CA2535242A1 (en) | 2003-08-15 | 2004-08-16 | Use of c-kit inhibitors for treating type ii diabetes |
JP2006523710A JP2007502809A (en) | 2003-08-15 | 2004-08-16 | Methods of using c-kit inhibitors for treating type II diabetes |
EP04769332A EP1653934B1 (en) | 2003-08-15 | 2004-08-16 | Use of c-kit inhibitors for treating type ii diabetes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49508803P | 2003-08-15 | 2003-08-15 | |
US60/495,088 | 2003-08-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005016323A2 true WO2005016323A2 (en) | 2005-02-24 |
WO2005016323A3 WO2005016323A3 (en) | 2005-04-07 |
Family
ID=34193274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2004/002934 WO2005016323A2 (en) | 2003-08-15 | 2004-08-16 | Use of c-kit inhibitors for treating type ii diabetes |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070032521A1 (en) |
EP (1) | EP1653934B1 (en) |
JP (1) | JP2007502809A (en) |
AT (1) | ATE395052T1 (en) |
CA (1) | CA2535242A1 (en) |
DE (1) | DE602004013792D1 (en) |
WO (1) | WO2005016323A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1702917A1 (en) * | 2003-12-25 | 2006-09-20 | Nippon Shinyaku Co., Ltd. | Amide derivative and medicine |
DE102005062986A1 (en) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | New substituted propiolic acid amides, useful for treatment and prevention of e.g. pain, anxiety and panic attacks, are inhibitors of the mGluR5 receptor |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
US7772254B2 (en) | 2003-09-22 | 2010-08-10 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
US7799807B2 (en) | 2003-09-22 | 2010-09-21 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
EP2366703A1 (en) | 2007-02-13 | 2011-09-21 | AB Science | Polymorph form of 2-amino (nitroaryl) thiazole derivative |
US8088806B2 (en) | 2005-05-09 | 2012-01-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
US8183263B2 (en) | 2007-05-22 | 2012-05-22 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles |
US9675544B2 (en) | 2008-01-22 | 2017-06-13 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
US9713613B2 (en) | 2007-02-02 | 2017-07-25 | Motonari Uesugi | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
US10357464B2 (en) | 2006-09-20 | 2019-07-23 | The Board Of Regents Of The University Of Texas System | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
WO2022036104A1 (en) * | 2020-08-12 | 2022-02-17 | University Of Iowa Research Foundation | Insulin sensitizers for the treatment of diabetes mellitus |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60134679D1 (en) * | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Nitrogen-containing aromatic heterocycles |
EP1604665B1 (en) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
EP1683785B1 (en) * | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
ES2322175T3 (en) * | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | MEDICINAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELIFICATION. |
WO2007015569A1 (en) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
JP4989476B2 (en) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Methods for assaying the effects of angiogenesis inhibitors |
WO2007026864A1 (en) * | 2005-09-01 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Method for preparation of pharmaceutical composition having improved disintegradability |
US20090053236A1 (en) * | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Anti-tumor agent for multiple myeloma |
WO2007136103A1 (en) * | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
JPWO2008001956A1 (en) * | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Liver fibrosis treatment |
WO2008026748A1 (en) * | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
KR101445892B1 (en) * | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Composition for treatment of undifferentiated-type of gastric cancer |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
MX2010008187A (en) * | 2008-01-29 | 2010-08-10 | Eisai R&D Man Co Ltd | Combined use of angiogenesis inhibitor and taxane. |
BR112012032462A2 (en) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | antitumor agent employing compounds which, in combination, have kinase inhibiting effect. |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
MX2015004979A (en) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Amorphous form of quinoline derivative, and method for producing same. |
ES2687968T3 (en) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarkers to predict and evaluate the reactivity of subjects with endometrial cancer to compounds with lenvatinib |
BR112017002827B1 (en) | 2014-08-28 | 2023-04-18 | Eisai R&D Management Co., Ltd | HIGHLY PURE QUINOLINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME |
MX2017010474A (en) | 2015-02-25 | 2017-11-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative. |
KR20240064733A (en) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0934931A2 (en) * | 1995-06-07 | 1999-08-11 | Sugen, Inc. | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators |
WO2001064200A2 (en) * | 2000-03-03 | 2001-09-07 | Novartis Ag | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
WO2004014903A1 (en) * | 2002-08-02 | 2004-02-19 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
WO2004076693A1 (en) * | 2003-02-27 | 2004-09-10 | Ab Science | Tailored treatment suitable for different forms of mastocytosis |
WO2004098612A2 (en) * | 2003-05-07 | 2004-11-18 | Ab Science | Calcitriol analogs of uses thereof |
WO2004105763A2 (en) * | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
-
2004
- 2004-08-16 EP EP04769332A patent/EP1653934B1/en not_active Expired - Lifetime
- 2004-08-16 DE DE602004013792T patent/DE602004013792D1/en not_active Expired - Fee Related
- 2004-08-16 CA CA002535242A patent/CA2535242A1/en not_active Abandoned
- 2004-08-16 WO PCT/IB2004/002934 patent/WO2005016323A2/en active IP Right Grant
- 2004-08-16 JP JP2006523710A patent/JP2007502809A/en active Pending
- 2004-08-16 US US10/567,557 patent/US20070032521A1/en not_active Abandoned
- 2004-08-16 AT AT04769332T patent/ATE395052T1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0934931A2 (en) * | 1995-06-07 | 1999-08-11 | Sugen, Inc. | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators |
WO2001064200A2 (en) * | 2000-03-03 | 2001-09-07 | Novartis Ag | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
WO2004014903A1 (en) * | 2002-08-02 | 2004-02-19 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
WO2004076693A1 (en) * | 2003-02-27 | 2004-09-10 | Ab Science | Tailored treatment suitable for different forms of mastocytosis |
WO2004098612A2 (en) * | 2003-05-07 | 2004-11-18 | Ab Science | Calcitriol analogs of uses thereof |
WO2004105763A2 (en) * | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
Non-Patent Citations (3)
Title |
---|
MA Y ET AL: "INDOLINONE DERIVATIVES INHIBIT CONSTITUTIVELY ACTIVATED KIT MUTANTS AND KILL NEOPLASTIC MAST CELLS" JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 114, no. 2, February 2001 (2001-02), pages 392-394, XP001127437 ISSN: 0022-202X * |
See also references of EP1653934A2 * |
ZERMATI Y ET AL: "Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c - kit receptors found i mast cell neoplasms" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 22, 2003, pages 660-664, XP002286458 ISSN: 0950-9232 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994177B2 (en) | 2003-09-22 | 2011-08-09 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
US8129388B2 (en) | 2003-09-22 | 2012-03-06 | Purde Pharma L.P. | Therapeutic agents useful for treating pain |
US7772254B2 (en) | 2003-09-22 | 2010-08-10 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
US7799807B2 (en) | 2003-09-22 | 2010-09-21 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
US7964606B2 (en) | 2003-09-22 | 2011-06-21 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
EP1702917A1 (en) * | 2003-12-25 | 2006-09-20 | Nippon Shinyaku Co., Ltd. | Amide derivative and medicine |
EP1702917A4 (en) * | 2003-12-25 | 2009-06-03 | Nippon Shinyaku Co Ltd | Amide derivative and medicine |
US8088806B2 (en) | 2005-05-09 | 2012-01-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
US8008304B2 (en) | 2005-12-28 | 2011-08-30 | Grüenthal GmbH | Substituted propiolic acid amides and their use for producing drugs |
WO2007079959A1 (en) * | 2005-12-28 | 2007-07-19 | Grünenthal GmbH | Substituted propiolic acid amides and their use for producing analgesics |
DE102005062986A1 (en) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | New substituted propiolic acid amides, useful for treatment and prevention of e.g. pain, anxiety and panic attacks, are inhibitors of the mGluR5 receptor |
US10799466B2 (en) | 2006-09-20 | 2020-10-13 | The Board Of Regents Of The University Of Texas System | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
US10357464B2 (en) | 2006-09-20 | 2019-07-23 | The Board Of Regents Of The University Of Texas System | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
US9713613B2 (en) | 2007-02-02 | 2017-07-25 | Motonari Uesugi | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
EP2366703A1 (en) | 2007-02-13 | 2011-09-21 | AB Science | Polymorph form of 2-amino (nitroaryl) thiazole derivative |
US8183263B2 (en) | 2007-05-22 | 2012-05-22 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
US9675544B2 (en) | 2008-01-22 | 2017-06-13 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
US10420720B2 (en) | 2008-01-22 | 2019-09-24 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
WO2022036104A1 (en) * | 2020-08-12 | 2022-02-17 | University Of Iowa Research Foundation | Insulin sensitizers for the treatment of diabetes mellitus |
Also Published As
Publication number | Publication date |
---|---|
US20070032521A1 (en) | 2007-02-08 |
CA2535242A1 (en) | 2005-02-24 |
EP1653934A2 (en) | 2006-05-10 |
WO2005016323A3 (en) | 2005-04-07 |
JP2007502809A (en) | 2007-02-15 |
DE602004013792D1 (en) | 2008-06-26 |
ATE395052T1 (en) | 2008-05-15 |
EP1653934B1 (en) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005016323A2 (en) | Use of c-kit inhibitors for treating type ii diabetes | |
KR101036866B1 (en) | 2-3-aminoarylamino-4-aryl-thiazoles and their use as c-kit inhibitors | |
US20070191267A1 (en) | Use of tyrosine kinase inhibitors for treating cerebral ischemia | |
CA2564568A1 (en) | Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy | |
WO2005115304A2 (en) | Use of c-kit inhibitors for treating fibrodysplasia | |
US8450302B2 (en) | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | |
US20070225293A1 (en) | Use of C-Kit Inhibitors for Treating Fibrosis | |
US8614222B2 (en) | Methods of preventing and treating low bone mass diseases | |
KR20160029024A (en) | Purine diones as wnt pathway modulators | |
AU6387799A (en) | Method for treating diabetes employing an ap2 inhibitor and combination | |
JP2007533731A (en) | Use of c-kit inhibitors for treating malaria parasite-related diseases | |
EP2282756A1 (en) | Methods of diagnosing, preventing and treating bone mass diseases | |
AU2003253195B2 (en) | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2535242 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004769332 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006523710 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004769332 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007032521 Country of ref document: US Ref document number: 10567557 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10567557 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004769332 Country of ref document: EP |